C-reactive protein: Informative or misleading marker of Crohn's disease?

Inflammatory Bowel Diseases

Volumn 13, Issue 4, 2007, Pages 501-502

  Franchimont, Denis ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CASPASE RECRUITMENT DOMAIN PROTEIN 15; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; STEROID;

ABDOMINAL PAIN; APPENDECTOMY; BODY MASS; CLINICAL FEATURE; CROHN DISEASE; DIARRHEA; DNA POLYMORPHISM; GENE MUTATION; HUMAN; ILEUM DISEASE; NOTE; PHENOTYPE; PRIORITY JOURNAL; RELAPSE; REMISSION; SMOKING HABIT; TREATMENT RESPONSE;

EID: 34247619220     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20123     Document Type: Note

References (9)

1. Florin TH, Paterson EW, Fowler EV, et al. Clinically active Crohn's disease in the presence of a low C-reactive protein. Scand J Gastroenterol. 2006;41:306-311.
2. Papadakis KA, Tabibzadeh S. Diagnosis and misdiagnosis of inflammatory bowel disease. Gastrointest Endosc Clin N Am. 2002;12:433-449.
3. Su C, Lichtenstein GR, Krok K, Brensinger CM, Lewis JD. A metaanalysis of the placebo rates of remission and response in clinical trials of active Crohn's disease. Gastroenterology. 2004;126:1257-1269.
4. Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis 2004;10:661-665.
5. Sandborn WJ, Colombel JF, Enns R, et al. Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med. 2005;353:1912-1925.
6. Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology. 2005;129:807-818.
7. Willot S, Vermeire S, Ohresser M, et al. No association between C-reactive protein gene polymorphisms and decrease of C-reactive protein serum concentration after infliximab treatment in Crohn's disease. Pharmacogenet Genomics. 2006;16:37-42.
8. Parsi MA, Achkar JP, Richardson S, et al. Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology. 2002;123:707-713.
9. Vermeire S, Louis E, Carbonez A, et al. Demographic and clinical parameters influencing the short term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. Am J Gastroenterol. 2002;97:2357-2363.